Regulatory

Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry

BioSpace

The FDA approved Eli Lilly's orforglipron--to be known as Foundayo--on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk's oral Wegovy.

Regulatory Metabolic & GLP-1 Read full story

pharminent April 1, 2026 (Last updated: April 1, 2026)

BioSpace

The FDA approved Eli Lilly’s orforglipron–to be known as Foundayo–on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.

Regulatory Metabolic & GLP-1 Read full story

Related Stories

FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients

FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy

Replimune gives cancer immunotherapy a third try after FDA leadership shakeup

You May Have Missed

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise